Buy Testosterones'Delatestryl'
http://www.buytestosterones.net/delatestryl/
2008-10-11T13:07:14+01:00text/htmlBusiness Wire - Alkermes and Indevus Announce Positive Results from Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
http://www.buytestosterones.net/testosterone-article/delatestryl/#business-wire----alkermes-and-indevus-announce-positive-results-from-phase-2a-clinical-study-of-alks-27-for-the-treatment-of-copd
September 26, 2007 -- - ALKS 27 Showed a Sustained Improvement in Lung Function Over 24 Hours - CAMBRIDGE & LEXINGTON, Mass. -- Alkermes, Inc. (NASDAQ: ALKS) and...text/htmlM2 Presswire - Morning Alert for Indevus Pharmaceuticals Inc.
http://www.buytestosterones.net/testosterone-article/delatestryl/#m2-presswire----morning-alert-for-indevus-pharmaceuticals-inc.
June 27, 2007 -- M2 PRESSWIRE-27 June 2007-Biotech News: Morning Alert for Indevus Pharmaceuticals Inc(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:27062007 Morning...text/htmlM2 Presswire - Current Research on Indevus Pharmaceuticals Inc.
http://www.buytestosterones.net/testosterone-article/delatestryl/#m2-presswire----current-research-on-indevus-pharmaceuticals-inc.
June 7, 2007 -- M2 PRESSWIRE-7 June 2007-Biotech News: Current Research on Indevus Pharmaceuticals Inc(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:07062007...text/htmlBusiness Wire - Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
http://www.buytestosterones.net/testosterone-article/delatestryl/#business-wire----alkermes-and-indevus-announce-initiation-of-phase-2a-clinical-study-of-alks-27-for-the-treatment-of-copd
April 25, 2007 -- CAMBRIDGE & LEXINGTON, Mass. -- Alkermes, Inc. (Nasdaq: ALKS) and Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced the initiation of...text/htmlM2 Presswire - Indevus Pharmaceuticals Inc is Added to the Bellwether Watch list.
http://www.buytestosterones.net/testosterone-article/delatestryl/#m2-presswire----indevus-pharmaceuticals-inc-is-added-to-the-bellwether-watch-list.
March 26, 2007 -- M2 PRESSWIRE-26 March 2007-Biotech News: Indevus Pharmaceuticals Inc is Added to the Bellwether Watch list(C)1994-2007 M2 COMMUNICATIONS LTD...text/htmlM2 Presswire - Analysis of Indevus Pharmaceuticals Inc.
http://www.buytestosterones.net/testosterone-article/delatestryl/#m2-presswire----analysis-of-indevus-pharmaceuticals-inc.
March 2, 2007 -- M2 PRESSWIRE-2 March 2007-Biotech News: Analysis of Indevus Pharmaceuticals Inc(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:02032007 Analysis of...text/htmlBusiness Wire - Alkermes and Indevus Announce Joint Collaboration to Develop Inhaled Formulation of Trospium Chloride for the Treatment of COPD
http://www.buytestosterones.net/testosterone-article/delatestryl/#business-wire----alkermes-and-indevus-announce-joint-collaboration-to-develop-inhaled-formulation-of-trospium-chloride-for-the-treatment-of-copd
January 4, 2007 -- -- Companies Report Phase 1 Study Results -- CAMBRIDGE, Mass. & LEXINGTON, Mass. -- Alkermes, Inc. (Nasdaq: ALKS) and Indevus Pharmaceuticals,...text/htmlM2 Presswire - Fundamental Review for Indevus Pharmaceuticals Inc.
http://www.buytestosterones.net/testosterone-article/delatestryl/#m2-presswire----fundamental-review-for-indevus-pharmaceuticals-inc.
December 12, 2006 -- M2 PRESSWIRE-12 December 2006-Biotech News: Fundamental Review for Indevus Pharmaceuticals Inc(C)1994-2006 M2 COMMUNICATIONS LTD RDATE:12122006...text/htmlBIOTECH Patent News - Indevus to acquire Valera.
http://www.buytestosterones.net/testosterone-article/delatestryl/#biotech-patent-news----indevus-to-acquire-valera.
December 1, 2006 -- Indevus Pharmaceuticals, Inc. (Lexington, MA) and Valera Pharmaceuticals, Inc. (Cranbury, NJ) have entered into a definitive agreement under which...text/htmlBusiness Wire - Savient Pharmaceuticals Reports Third Quarter Financial Results
http://www.buytestosterones.net/testosterone-article/delatestryl/#business-wire----savient-pharmaceuticals-reports-third-quarter-financial-results
October 30, 2006 -- Operating Profits from Continuing Operations of $1.6 Million for the Quarter EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT)...